LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION

J. Barrientos
S. Coutre
S. De Vos
I. Flinn
N. Wagner-Johnston
M. Schreeder
J. Sharman
T. Boyd
K. Rai
J. Leonard
B. Sorensen
A. Viggiano
T. Jahn
R. Furman

Abstract